Covered recipient · General Payments record
DOUGLAS R ADKINS
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$141,544.04
- Reported across 140 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,610.00 | 2 |
| Food and Beverage | $518.54 | 5 |
| Travel and Lodging | $512.33 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genmab U.S., Inc. | $5,998.25 | 7 |
| Regeneron Pharmaceuticals, Inc. | $2,360.00 | 1 |
| Coherus Biosciences Inc. | $282.62 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc. | $140.35 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147276308 | CMS |
| Coherus Biosciences Inc. | $142.27 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147276306 | CMS |
| Genmab U.S., Inc. | $198.47 | 07/23/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126826108 | CMS |
| Genmab U.S., Inc. | $119.60 | 08/16/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126826098 | CMS |
| Genmab U.S., Inc. | $120.06 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126826100 | CMS |
| Genmab U.S., Inc. | $194.26 | 08/16/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1126826104 | CMS |
| Genmab U.S., Inc. | $65.07 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126826106 | CMS |
| Genmab U.S., Inc. | $50.79 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126826110 | CMS |
| Genmab U.S., Inc. | $5,250.00 | 08/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1126826102 | CMS |
| Regeneron Pharmaceuticals, Inc. | $2,360.00 | 01/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114395824 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.